Holen Sie sich die Stockscreener-App
5.775
46.43%
1.435
Opus Genetics Inc Aktie (IRD) Neueste Nachrichten
Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving High - Benzinga
IRD Stock Jumps As Traders Target Gene Therapy Catalyst - timothysykes.com
IRD Stock Eyes Webcast Catalyst As Gene Therapy Data Nears - StocksToTrade
IRD Maintained by Chardan Capital -- Price Target at $13.00 - GuruFocus
Opus Genetics Reports Positive OPGx-BEST1 Phase 1/2 Data - TipRanks
IRD Looks 1451.8% Overvalued on GF Value™ - GuruFocus
Opus Genetics Reports Positive Interim Phase 1/2 Results for OPGx-BEST1 in BEST1-Related Retinal Diseases - Quiver Quantitative
Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027 - Yahoo Finance
Opus Genetics Director Cam Gallagher Exercises Warrant for 784,314 Shares, Enters 180-Day Lock-Up - Kalkine Media
Opus Genetics (IRD) director adds shares, accepts 180-day lock-up - Stock Titan
Opus Genetics (IRD) CFO stock sale mixes tax withholding and 10b5-1 plan - Stock Titan
Opus Genetics gets Buy rating ahead of key gene therapy data release on Sept 9, 2026. - Pluang
Opus Genetics stock rating reaffirmed at Buy by H.C. Wainwright - Investing.com
Missed Opus Genetics' 130% Run? The Story Isn't Over Yet - RTTNews
LifeSci Capital Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Opus Genetics to Present Topline Phase 1/2 OPGx-BEST1 Gene Therapy Data on September 9 - Quiver Quantitative
Opus Genetics Plans OPGx-BEST1 Data Webcast Sept. 9 | IRD Stock News - Stock Titan
Opus Genetics shares rise 5.9% ahead of OPGx-BEST1 trial data - Yahoo Finance
Why is Opus Genetics stock rallying today? By Investing.com - Investing.com Nigeria
Why is Opus Genetics stock rallying today? - Investing.com
IRD | Opus Genetics, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
Citizens reiterates Opus Genetics stock rating on Viatris partnership potential By Investing.com - Investing.com Nigeria
Opus (IRD) Quarterly Figures: Profit Per Share Clears Its Benchmark in the Latest Session; Price Reaction - vinanet.vn
Opus (IRD) Earnings Report: Profit Per Share Clears Its Benchmark on the Day; After Results: The Market Price Declines 1.70% in the Current UpdateWeak Earnings Momentum - vinanet.vn
Opus Genetics, Inc. (NASDAQ: IRD) Share Price, IRD Stock News, IRD Share Price & Updates - Kalkine
Balyasny Asset Management L.P. Expands Opus Genetics Inc (IRD) S - GuruFocus
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Opus Genetics stock maintains buy rating ahead of trial data By Investing.com - Investing.com Canada
Citizens reiterates Opus Genetics stock rating ahead of trial data - Investing.com
Citizens reiterates Opus Genetics stock rating ahead of trial data By Investing.com - Investing.com India
Wall Street Zen Upgrades Opus Genetics (NASDAQ:IRD) to "Hold" - MarketBeat
IRD Q2 2026 Earnings: Narrower-than-Expected Loss of -$0.14 Beats Estimates, Though Shares Slip 2.96%Profitability Analysis - vinanet.vn
Opus Genetics (NASDAQ:IRD) Rating Increased to Hold at Zacks Research - MarketBeat
Opus Genetics Q3 EPS Lifted by Brookline Capital Markets - MarketBeat
Brokers Set Expectations for Opus Genetics FY2030 Earnings - MarketBeat
Opus Genetics FY2026 EPS Estimate Boosted by HC Wainwright - MarketBeat
Opus Genetics, Inc. (NASDAQ:IRD) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
How FDA Alignment Is Shaping Opus Genetics' OPGx-LCA5 Development Strategy - Clinical Leader
Opus Genetics completes phase 3 enrollment for OPGx-LCA5 gene therapy - Glance by Eyes On Eyecare
Opus Genetics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Opus Genetics Inc (IRD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Opus Genetics (IRD) Gets a Buy from RBC Capital - The Globe and Mail
Piper Sandler Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Is Opus Genetics Inc (IRD) Significantly Overvalued After Q2 Ear - GuruFocus
Opus Genetics (IRD) Q1 2026 Earnings: Deep EPS Miss Heightens Scrutiny on Clinical-Stage SpendingEarnings Trend Analysis - dars.gov.et
OPUS GENETICSMAY OFFER AND SELL UP TO $300 MLN OF SECURITIESSEC FILING - Moomoo
Opus Genetics (NASDAQ:IRD) Upgraded at Wall Street Zen - MarketBeat
IRD Maintained by RBC Capital -- Price Target Lowered to $9.00 - GuruFocus
A. G. P. Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $9 - Moomoo
A Quick Look at Today's Ratings for Opus Genetics(IRD.US), With a Forecast Between $9 to $10 - Moomoo
Opus GeneticsMay Offer And Sell Up To $300 Million Of SecuritiesSEC Filing - TradingView
RBC Adjusts PT on Opus Genetics to $9 From $10, Maintains Outperform Speculative Risk Rating - marketscreener.com
Opus Genetics (NASDAQ: IRD) sets $300M shelf and $125M ATM stock plan - Stock Titan
Opus Genetics earnings beat by $0.02, revenue fell short of estimates - Investing.com Canada
Opus Genetics (NASDAQ:IRD) Releases Earnings Results - MarketBeat
Opus Genetics, Inc. 2Q 2026: Revenue $0.8M, EPS $(0.14) — 10-Q Summary - TradingView
Opus Genetics (Nasdaq: IRD) hit by $73.6M loss, rising warrant costs - Stock Titan
Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update - The Manila Times
Opus Genetics Q2 revenue falls and misses estimates - TradingView
IRD: Gene therapy pipeline advances with strong cash position and key clinical milestones ahead - TradingView
Opus Genetics Reports Q2 2026 Results and Advances Multiple IRD Gene Therapy Programs with OPGx-BEST1 Data Expected in September - Quiver Quantitative
Opus Genetics reports Q2 2026 results: $0.8M revenue, $8.1M net loss, $88.8M cash - TradingView
Opus Genetics Completes Phase 3 Enrollment for AAV Gene Therapy OPGx-LCA5 - BioPharm International
Opus Genetics (IRD) to Release Quarterly Earnings on Wednesday - MarketBeat
1.30%
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):